Kezar Life Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Balance Sheet Components

Balance Sheet Components

12 Months Ended

Dec. 31, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Balance Sheet Components

5. Balance Sheet Components

Property and Equipment, Net

Property and equipment consists of the following (in thousands):

	December 31, 2019			December 31, 2018
Leasehold improvements	$	3,268		$	3,268
Furniture, laboratory and office equipment		2,578			2,043
Computer equipment		253			219
Total property and equipment		6,099			5,530
Less accumulated depreciation and amortization		(1,817	)		(935	)
Property and equipment, net	$	4,282		$	4,595

Depreciation expense was $0.9 million for the year ended December 31, 2019, $0.7 million for the year ended December 31, 2018 and $0.2 million for the year ended December 31, 2017.

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	December 31, 2019		December 31, 2018
Accrued preclinical and research costs	$	1,687	$	1,146
Accrued clinical costs		1,027		434
Accrued employee-related costs		1,293		736
Accrued professional services		53		138
Other		158		224
Total accrued liabilities	$	4,218	$	2,678